Crossmark

Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial)

Crossref DOI link: https://doi.org/10.1186/s12874-018-0581-z

Published Online: 2018-11-06

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Murray, Macey L.

Meadows, Jade

Doré, Caroline J.

Copas, Andrew J.

Haddow, Lewis J.

Lacey, Charles

Jit, Mark

Soldan, Kate

Bennett, Kate

Tetlow, Michelle

Nathan, Mayura

Gilson, Richard https://orcid.org/0000-0002-9572-193X
Funding

Funding for this research was provided by:

Health Technology Assessment Programme (11/129/187)
License Information

Text and Data Mining valid from 2018-11-06
More Information

Article History

Received: 21 December 2017

Accepted: 18 October 2018

First Online: 6 November 2018

Ethics approval and consent to participate

: The trial protocol was reviewed by the Oxfordshire Research Ethics Committee B (reference 13/SC/0638). Written informed consent is sought from each participant prior to enrolment.

: Not applicable

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below